Header Logo

Connection

Usman Baber to Drug Therapy, Combination

Back to Details
This is a "connection" page, showing publications Usman Baber has written about Drug Therapy, Combination.
Usman Baber
Connection Strength
3.372
Drug Therapy, Combination
  1. Antiplatelet Therapy for Patients Who Have Undergone Revascularization Within the Past Year: Which Agents and for How Long? Med Clin North Am. 2024 May; 108(3):539-551.
    View in: PubMed
    Score: 0.214
  2. The 5W1H in antiplatelet monotherapy after percutaneous coronary intervention: what, who, where, when, why, and how? Rev Esp Cardiol (Engl Ed). 2022 Feb; 75(2):115-118.
    View in: PubMed
    Score: 0.184
  3. Extending the aspirin-free paradigm to patients with acute coronary syndrome: is it time to change guidelines? EuroIntervention. 2020 Oct 23; 16(8):620-622.
    View in: PubMed
    Score: 0.172
  4. The Role of Aspirin After High-Risk Percutaneous Coronary Intervention: The Ticagrelor with Aspirin or Alone in High-Risk Patients After Coronary Intervention Clinical Trial Experience. Interv Cardiol Clin. 2020 10; 9(4):489-498.
    View in: PubMed
    Score: 0.171
  5. Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS. Eur Heart J. 2020 10 01; 41(37):3533-3545.
    View in: PubMed
    Score: 0.171
  6. Ticagrelor With or Without Aspirin After PCI: The TWILIGHT Platelet Substudy. J Am Coll Cardiol. 2020 02 18; 75(6):578-586.
    View in: PubMed
    Score: 0.164
  7. Clinical trials in long-term antiplatelet therapies: focus on the role of aspirin. Curr Opin Cardiol. 2019 07; 34(4):315-322.
    View in: PubMed
    Score: 0.157
  8. Incidence, Patterns, and Impact of Dual Antiplatelet Therapy Cessation Among Patients With and Without Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention: Results From the PARIS Registry (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients). Circ Cardiovasc Interv. 2018 03; 11(3):e006144.
    View in: PubMed
    Score: 0.143
  9. Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study. Am Heart J. 2016 Dec; 182:125-134.
    View in: PubMed
    Score: 0.129
  10. Time-Dependent Associations Between Actionable Bleeding, Coronary Thrombotic Events, and Mortality Following Percutaneous Coronary Intervention: Results From the PARIS Registry. JACC Cardiovasc Interv. 2016 07 11; 9(13):1349-57.
    View in: PubMed
    Score: 0.127
  11. Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS. J Am Coll Cardiol. 2016 May 17; 67(19):2224-2234.
    View in: PubMed
    Score: 0.125
  12. Antithrombotic strategy variability in ATrial fibrillation and obstructive coronary disease revascularized with PCI-rationale and study design of the prospective observational multicenter AVIATOR 2 registry. Am Heart J. 2015 Dec; 170(6):1234-42.
    View in: PubMed
    Score: 0.121
  13. Efficacy of modified dual antiplatelet therapy combined with warfarin following percutaneous coronary intervention with drug-eluting stents. J Invasive Cardiol. 2010 Feb; 22(2):80-3.
    View in: PubMed
    Score: 0.082
  14. Dyspnea-Related Ticagrelor Discontinuation After Percutaneous?Coronary Intervention. JACC Cardiovasc Interv. 2023 10 23; 16(20):2514-2524.
    View in: PubMed
    Score: 0.053
  15. P2Y12 Inhibitor Monotherapy or Dual Antiplatelet Therapy After Complex Percutaneous Coronary Interventions. J Am Coll Cardiol. 2023 02 14; 81(6):537-552.
    View in: PubMed
    Score: 0.050
  16. Ticagrelor with and without aspirin in patients with a prior coronary artery bypass graft undergoing percutaneous coronary intervention: the TWILIGHT-CABG study. EuroIntervention. 2022 Dec 02; 18(11):e897-e909.
    View in: PubMed
    Score: 0.050
  17. Bleeding and Ischemic Outcomes With Ticagrelor Monotherapy According to Body Mass Index. JACC Cardiovasc Interv. 2022 10 10; 15(19):1948-1960.
    View in: PubMed
    Score: 0.049
  18. Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD. Eur Heart J Cardiovasc Pharmacother. 2022 Sep 29; 8(7):707-716.
    View in: PubMed
    Score: 0.049
  19. Ticagrelor With or Without Aspirin in Chinese Patients Undergoing Percutaneous Coronary Intervention: A TWILIGHT China Substudy. Circ Cardiovasc Interv. 2022 04; 15(4):e009495.
    View in: PubMed
    Score: 0.047
  20. Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI: A Prespecified TWILIGHT Substudy. JACC Cardiovasc Interv. 2022 02 14; 15(3):282-293.
    View in: PubMed
    Score: 0.047
  21. Ticagrelor monotherapy in patients with chronic kidney disease undergoing percutaneous coronary intervention: TWILIGHT-CKD. Eur Heart J. 2021 12 01; 42(45):4683-4693.
    View in: PubMed
    Score: 0.046
  22. Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR. Eur Heart J. 2021 12 01; 42(45):4624-4634.
    View in: PubMed
    Score: 0.046
  23. Sex Differences Among Patients With High Risk Receiving Ticagrelor With or Without Aspirin After Percutaneous Coronary Intervention: A Subgroup Analysis of the TWILIGHT Randomized Clinical Trial. JAMA Cardiol. 2021 09 01; 6(9):1032-1041.
    View in: PubMed
    Score: 0.046
  24. Impact of Age on the Safety and Efficacy of Ticagrelor Monotherapy in Patients Undergoing PCI. JACC Cardiovasc Interv. 2021 07 12; 14(13):1434-1446.
    View in: PubMed
    Score: 0.045
  25. Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI: An Individual Patient-Level Meta-Analysis. JACC Cardiovasc Interv. 2021 02 22; 14(4):444-456.
    View in: PubMed
    Score: 0.044
  26. Ticagrelor monotherapy beyond one month after PCI in ACS or stable CAD in elderly patients: a pre-specified analysis of the GLOBAL LEADERS trial. EuroIntervention. 2020 Apr 03; 15(18):e1605-e1614.
    View in: PubMed
    Score: 0.041
  27. Ticagrelor With or Without Aspirin in High-Risk Patients With Diabetes Mellitus Undergoing Percutaneous Coronary Intervention. J Am Coll Cardiol. 2020 05 19; 75(19):2403-2413.
    View in: PubMed
    Score: 0.041
  28. Ticagrelor With or Without Aspirin After Complex PCI. J Am Coll Cardiol. 2020 05 19; 75(19):2414-2424.
    View in: PubMed
    Score: 0.041
  29. Long-Term Safety and Efficacy of Durable Polymer Cobalt-Chromium Everolimus-Eluting Stents in Patients at High Bleeding Risk: A Patient-Level Stratified Analysis From Four Postapproval Studies. Circulation. 2020 03 17; 141(11):891-901.
    View in: PubMed
    Score: 0.041
  30. Ticagrelor with or without Aspirin in High-Risk Patients after PCI. N Engl J Med. 2019 11 21; 381(21):2032-2042.
    View in: PubMed
    Score: 0.040
  31. Dual-Antiplatelet Therapy Cessation and Cardiovascular Risk in Relation to Age: Analysis From the PARIS Registry. JACC Cardiovasc Interv. 2019 05 27; 12(10):983-992.
    View in: PubMed
    Score: 0.039
  32. Influence of Baseline Anemia on Dual Antiplatelet Therapy Cessation and Risk of Adverse Events After Percutaneous Coronary Intervention. Circ Cardiovasc Interv. 2019 04; 12(4):e007133.
    View in: PubMed
    Score: 0.038
  33. Patterns and Impact of Dual Antiplatelet Cessation on Cardiovascular Risk After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes. Am J Cardiol. 2019 03 01; 123(5):709-716.
    View in: PubMed
    Score: 0.038
  34. Dual Antiplatelet Therapy Cessation and Adverse Events After Drug-Eluting Stent Implantation in Patients at High Risk for Atherothrombosis (from the PARIS Registry). Am J Cardiol. 2018 11 15; 122(10):1638-1646.
    View in: PubMed
    Score: 0.037
  35. Sex differences in the effect of diabetes mellitus on platelet reactivity and coronary thrombosis: From the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents (ADAPT-DES) study. Int J Cardiol. 2017 Nov 01; 246:20-25.
    View in: PubMed
    Score: 0.035
  36. White Blood Cell Count and Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in the Contemporary Era: Insights From the PARIS Study (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients Registry). Circ Cardiovasc Interv. 2017 Sep; 10(9).
    View in: PubMed
    Score: 0.034
  37. Causes, Timing, and Impact of Dual Antiplatelet Therapy Interruption for Surgery (from the Patterns of Non-adherence to Anti-platelet Regimens In Stented Patients Registry). Am J Cardiol. 2017 Sep 15; 120(6):904-910.
    View in: PubMed
    Score: 0.034
  38. Patterns and associations between DAPT cessation and 2-year clinical outcomes in left main/proximal LAD versus other PCI: Results from the Patterns of Non-Adherence to Dual Antiplatelet Therapy in Stented Patients (PARIS) registry. Int J Cardiol. 2017 Sep 15; 243:132-139.
    View in: PubMed
    Score: 0.034
  39. Incidence, Patterns, and Associations Between Dual-Antiplatelet Therapy Cessation and Risk for Adverse Events Among Patients With and Without Diabetes Mellitus Receiving Drug-Eluting Stents: Results From the PARIS Registry. JACC Cardiovasc Interv. 2017 04 10; 10(7):645-654.
    View in: PubMed
    Score: 0.033
  40. Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents). Circ Cardiovasc Interv. 2017 02; 10(2).
    View in: PubMed
    Score: 0.033
  41. Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study. Am Heart J. 2017 Feb; 184:81-87.
    View in: PubMed
    Score: 0.033
  42. Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry. Catheter Cardiovasc Interv. 2017 Jun 01; 89(7):E217-E225.
    View in: PubMed
    Score: 0.032
  43. Sex-Based Differences in Cessation of Dual-Antiplatelet Therapy Following Percutaneous Coronary Intervention With Stents. JACC Cardiovasc Interv. 2016 07 25; 9(14):1461-9.
    View in: PubMed
    Score: 0.032
  44. Exome sequencing of extreme clopidogrel response phenotypes identifies B4GALT2 as a determinant of on-treatment platelet reactivity. Clin Pharmacol Ther. 2016 09; 100(3):287-94.
    View in: PubMed
    Score: 0.032
  45. Sex-related differences in outcomes among men and women under 55 years of age with acute coronary syndrome undergoing percutaneous coronary intervention: Results from the PROMETHEUS study. Catheter Cardiovasc Interv. 2017 Mar 01; 89(4):629-637.
    View in: PubMed
    Score: 0.032
  46. Impact of Anemia on Platelet Reactivity and Ischemic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study. Am J Cardiol. 2016 Jun 15; 117(12):1877-83.
    View in: PubMed
    Score: 0.031
  47. Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2016 Sep 06; 134(10):e156-78.
    View in: PubMed
    Score: 0.031
  48. Relation Between Platelet Count and Platelet Reactivity to Thrombotic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study. Am J Cardiol. 2016 Jun 01; 117(11):1703-13.
    View in: PubMed
    Score: 0.031
  49. Current developments in dual antiplatelet therapy after stenting. Minerva Cardioangiol. 2014 Jun; 62(3):261-76.
    View in: PubMed
    Score: 0.028
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.